People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway. After receiving three doses at six-month intervals, extending the time between following doses to nine months is “a safe and effective…
Read more
I knew that starting my college journey in a a different city, less than a year after receiving my relapsing-remitting multiple sclerosis (RRMS) diagnosis, would be challenging because I didn’t fully understand what was happening in my body. Even though my college, the University of Texas at Austin,…
A small molecule that blocks the activity of a protein called TYK2 in the brain showed promise at reducing disease activity in mouse models of multiple sclerosis (MS), according to a study. The study was conducted by Neuron23, which is advancing a small molecule TYK2 inhibitor called NEU-627…
Recently, my work-life balance felt off, so I took the opportunity to house-sit a family farm. I needed the solitude — the peace and quiet — to recharge. While there, I watched a flock of 50 to 60 goldfinches gather at the bird feeders daily. Their communal nature fascinated me,…
Get regular updates to your inbox.
